Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 3.36
ICCC's Cash to Debt is ranked lower than
66% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. ICCC: 3.36 )
Ranked among companies with meaningful Cash to Debt only.
ICCC' s Cash to Debt Range Over the Past 10 Years
Min: 1  Med: 4.75 Max: No Debt
Current: 3.36
Equity to Asset 0.79
ICCC's Equity to Asset is ranked higher than
63% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ICCC: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
ICCC' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.85 Max: 0.97
Current: 0.79
0.57
0.97
Interest Coverage 13.70
ICCC's Interest Coverage is ranked lower than
83% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ICCC: 13.70 )
Ranked among companies with meaningful Interest Coverage only.
ICCC' s Interest Coverage Range Over the Past 10 Years
Min: 3.27  Med: No Debt Max: No Debt
Current: 13.7
F-Score: 6
Z-Score: 5.81
M-Score: -2.66
WACC vs ROIC
11.48%
14.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.17
ICCC's Operating margin (%) is ranked higher than
85% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. ICCC: 17.17 )
Ranked among companies with meaningful Operating margin (%) only.
ICCC' s Operating margin (%) Range Over the Past 10 Years
Min: -25.21  Med: -1.52 Max: 20.74
Current: 17.17
-25.21
20.74
Net-margin (%) 10.29
ICCC's Net-margin (%) is ranked higher than
81% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. ICCC: 10.29 )
Ranked among companies with meaningful Net-margin (%) only.
ICCC' s Net-margin (%) Range Over the Past 10 Years
Min: -10.12  Med: -0.27 Max: 13.48
Current: 10.29
-10.12
13.48
ROE (%) 8.53
ICCC's ROE (%) is ranked higher than
84% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. ICCC: 8.53 )
Ranked among companies with meaningful ROE (%) only.
ICCC' s ROE (%) Range Over the Past 10 Years
Min: -4.76  Med: -0.4 Max: 12.21
Current: 8.53
-4.76
12.21
ROA (%) 6.68
ICCC's ROA (%) is ranked higher than
87% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. ICCC: 6.68 )
Ranked among companies with meaningful ROA (%) only.
ICCC' s ROA (%) Range Over the Past 10 Years
Min: -4.57  Med: -0.35 Max: 9.46
Current: 6.68
-4.57
9.46
ROC (Joel Greenblatt) (%) 25.83
ICCC's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. ICCC: 25.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICCC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -27.93  Med: 0.71 Max: 35.79
Current: 25.83
-27.93
35.79
Revenue Growth (3Y)(%) 23.10
ICCC's Revenue Growth (3Y)(%) is ranked higher than
78% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ICCC: 23.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ICCC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.4  Med: 4.7 Max: 23.1
Current: 23.1
-19.4
23.1
EBITDA Growth (3Y)(%) 59.50
ICCC's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. ICCC: 59.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ICCC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 24.4 Max: 99.4
Current: 59.5
0
99.4
EPS Growth (3Y)(%) 133.10
ICCC's EPS Growth (3Y)(%) is ranked higher than
98% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ICCC: 133.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ICCC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.5  Med: 3.75 Max: 133.1
Current: 133.1
-42.5
133.1
» ICCC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ICCC Guru Trades in Q3 2015

Jim Simons 45,200 sh (+63.18%)
» More
Q4 2015

ICCC Guru Trades in Q4 2015

Jim Simons 47,800 sh (+5.75%)
» More
Q1 2016

ICCC Guru Trades in Q1 2016

Jim Simons 56,707 sh (+18.63%)
» More
Q2 2016

ICCC Guru Trades in Q2 2016

Jim Simons 64,200 sh (+13.21%)
» More
» Details

Insider Trades

Latest Guru Trades with ICCC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:HTBX, OTCPK:CLCS, NAS:OPXA, AMEX:CANF, NAS:MRNS, OTCPK:QBIO, OTCPK:LVCLF, NAS:CERU, NAS:CUR, NAS:APTO, NAS:PULM, NAS:SBOT, NAS:CLBS, NAS:ONCS, OTCPK:CSBTF, OTCPK:FENCF, NAS:ABIO, OTCBB:DDRT, NAS:VTGN, OTCPK:PTGEF » details
Traded in other countries:IUL.Germany,
ImmuCell Corp is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include First Defense, Wipe Out Dairy Wipes and CMT.

ImmuCell Corporation was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987. It completed an initial public offering of common stock in 1987. The Company is engaged in the development, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industry. Its purpose is to create scientifically proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. At the same time, it is investigating ways to develop new products utilizing First Defense and Nisin technologies. Its product, First Defense, is manufactured from cows' colostrum using its proprietary vaccine and whey protein purification technologies. The target disease, bovine enteritis (calf scours), causes diarrhea and dehydration in newborn calves and often leads to serious sickness and even death. First DefenseÒ is the only USDA-licensed, orally delivered scours preventive product on the market for calves with claims against E. coli K99 and coronavirus. During the fourth quarter of 2011, it sold the 11,000,000th dose of First DefenseÒ, since receiving USDA approval of this product in 1991. In 1999, it acquired Wipe OutÒ Dairy Wipes, which is its second source of product sales revenue. That transaction included the purchase of certain equipment, trademarks and a license of intellectual property, including several issued patents, covering the product and rights to develop skin and environmental sanitizing applications of the Nisin technology. Wipe OutÒ Dairy Wipes consist of biodegradable towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking. Nisin is an antibacterial peptide that has been demonstrated in clinical studies to be an effective aid in the reduction of mastitis-causing organisms in dairy cows. First DefenseÒ is generally sold through large, financially strong distributors, which it believes has resulted in minimal bad debt with respect to this product. The Company provides for a 50% account credit for domestic distributors on expired First DefenseÒ product, which has a two-year shelf life resulting in an immaterial amount of returns. The Company's competition in the animal health market includes other biotechnology companies and major animal health companies. In addition to direct competition from oral antibody products, First DefenseÒ also competes for market share against vaccine products that are used to increase the production of antibodies by the dam that can then be transferred through the mother's milk to the calf and against vaccine products that are administered to the newborn calf.

Ratios

vs
industry
vs
history
P/E(ttm) 23.22
ICCC's P/E(ttm) is ranked higher than
59% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 28.72 vs. ICCC: 23.22 )
Ranked among companies with meaningful P/E(ttm) only.
ICCC' s P/E(ttm) Range Over the Past 10 Years
Min: 14.57  Med: 26.02 Max: 669
Current: 23.22
14.57
669
PE(NRI) 23.22
ICCC's PE(NRI) is ranked higher than
59% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ICCC: 23.22 )
Ranked among companies with meaningful PE(NRI) only.
ICCC' s PE(NRI) Range Over the Past 10 Years
Min: 14.57  Med: 26.02 Max: 334.5
Current: 23.22
14.57
334.5
Price/Owner Earnings (ttm) 48.65
ICCC's Price/Owner Earnings (ttm) is ranked lower than
59% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 33.65 vs. ICCC: 48.65 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ICCC' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.99  Med: 25.29 Max: 4820
Current: 48.65
8.99
4820
P/B 1.88
ICCC's P/B is ranked higher than
77% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. ICCC: 1.88 )
Ranked among companies with meaningful P/B only.
ICCC' s P/B Range Over the Past 10 Years
Min: 0.41  Med: 1.5 Max: 3.38
Current: 1.88
0.41
3.38
P/S 2.45
ICCC's P/S is ranked higher than
83% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. ICCC: 2.45 )
Ranked among companies with meaningful P/S only.
ICCC' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 2.31 Max: 4.84
Current: 2.45
0.87
4.84
POCF 15.17
ICCC's POCF is ranked higher than
66% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 22.41 vs. ICCC: 15.17 )
Ranked among companies with meaningful POCF only.
ICCC' s POCF Range Over the Past 10 Years
Min: 6.39  Med: 16.66 Max: 139.29
Current: 15.17
6.39
139.29
EV-to-EBIT 12.42
ICCC's EV-to-EBIT is ranked higher than
70% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. ICCC: 12.42 )
Ranked among companies with meaningful EV-to-EBIT only.
ICCC' s EV-to-EBIT Range Over the Past 10 Years
Min: -105.8  Med: 8 Max: 107.3
Current: 12.42
-105.8
107.3
EV-to-EBITDA 9.08
ICCC's EV-to-EBITDA is ranked higher than
75% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. ICCC: 9.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICCC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -119.3  Med: 6.7 Max: 159.2
Current: 9.08
-119.3
159.2
Shiller P/E 175.66
ICCC's Shiller P/E is ranked lower than
89% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.61 vs. ICCC: 175.66 )
Ranked among companies with meaningful Shiller P/E only.
ICCC' s Shiller P/E Range Over the Past 10 Years
Min: 5.31  Med: 46.73 Max: 275
Current: 175.66
5.31
275
Current Ratio 11.92
ICCC's Current Ratio is ranked higher than
81% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. ICCC: 11.92 )
Ranked among companies with meaningful Current Ratio only.
ICCC' s Current Ratio Range Over the Past 10 Years
Min: 2.71  Med: 8.98 Max: 30.82
Current: 11.92
2.71
30.82
Quick Ratio 10.79
ICCC's Quick Ratio is ranked higher than
79% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ICCC: 10.79 )
Ranked among companies with meaningful Quick Ratio only.
ICCC' s Quick Ratio Range Over the Past 10 Years
Min: 1.71  Med: 7.63 Max: 26.79
Current: 10.79
1.71
26.79
Days Inventory 78.60
ICCC's Days Inventory is ranked higher than
69% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. ICCC: 78.60 )
Ranked among companies with meaningful Days Inventory only.
ICCC' s Days Inventory Range Over the Past 10 Years
Min: 78.6  Med: 145.25 Max: 259.57
Current: 78.6
78.6
259.57
Days Sales Outstanding 32.83
ICCC's Days Sales Outstanding is ranked higher than
74% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. ICCC: 32.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICCC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.71  Med: 38.3 Max: 47.52
Current: 32.83
24.71
47.52
Days Payable 48.20
ICCC's Days Payable is ranked lower than
54% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. ICCC: 48.20 )
Ranked among companies with meaningful Days Payable only.
ICCC' s Days Payable Range Over the Past 10 Years
Min: 14.55  Med: 24.04 Max: 52.87
Current: 48.2
14.55
52.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
ICCC's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ICCC: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICCC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4  Med: -0.9 Max: -0.3
Current: -0.4
-4
-0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.97
ICCC's Price/Net Cash is ranked higher than
58% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ICCC: 4.97 )
Ranked among companies with meaningful Price/Net Cash only.
ICCC' s Price/Net Cash Range Over the Past 10 Years
Min: 1.05  Med: 4.07 Max: 61.75
Current: 4.97
1.05
61.75
Price/Net Current Asset Value 3.43
ICCC's Price/Net Current Asset Value is ranked higher than
70% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. ICCC: 3.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICCC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.77  Med: 2.72 Max: 12.04
Current: 3.43
0.77
12.04
Price/Tangible Book 1.88
ICCC's Price/Tangible Book is ranked higher than
81% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ICCC: 1.88 )
Ranked among companies with meaningful Price/Tangible Book only.
ICCC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.5  Med: 1.65 Max: 4.29
Current: 1.88
0.5
4.29
Price/Projected FCF 3.36
ICCC's Price/Projected FCF is ranked lower than
51% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. ICCC: 3.36 )
Ranked among companies with meaningful Price/Projected FCF only.
ICCC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.58 Max: 85.17
Current: 3.36
0.49
85.17
Price/Median PS Value 1.06
ICCC's Price/Median PS Value is ranked lower than
56% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ICCC: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
ICCC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 0.93 Max: 2.4
Current: 1.06
0.27
2.4
Price/Peter Lynch Fair Value 0.64
ICCC's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 1.64 vs. ICCC: 0.64 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ICCC' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 0.48 Max: 3.8
Current: 0.64
0
3.8
Price/Graham Number 1.40
ICCC's Price/Graham Number is ranked higher than
78% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. ICCC: 1.40 )
Ranked among companies with meaningful Price/Graham Number only.
ICCC' s Price/Graham Number Range Over the Past 10 Years
Min: 0.26  Med: 1.34 Max: 5
Current: 1.4
0.26
5
Earnings Yield (Greenblatt) (%) 8.00
ICCC's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ICCC: 8.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICCC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.9  Med: 6.9 Max: 870.3
Current: 8
0.9
870.3
Forward Rate of Return (Yacktman) (%) 39.74
ICCC's Forward Rate of Return (Yacktman) (%) is ranked higher than
90% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.44 vs. ICCC: 39.74 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ICCC' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -7.8  Med: -1.3 Max: 39.74
Current: 39.74
-7.8
39.74

More Statistics

Revenue (TTM) (Mil) $10.53
EPS (TTM) $ 0.31
Beta1.41
Short Percentage of Float0.10%
52-Week Range $5.60 - 8.29
Shares Outstanding (Mil)4.18
» More Articles for NAS:ICCC

Headlines

Articles On GuruFocus.com
ImmuCell Corp. Reports Operating Results (10-Q) Nov 08 2010 
ImmuCell Corp. Reports Operating Results (10-Q) Aug 16 2010 
ImmuCell Corp. Reports Operating Results (10-Q) May 06 2010 
ImmuCell Corp. Reports Operating Results (10-Q) Nov 04 2009 
ImmuCell Corp. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
IMMUCELL CORP /DE/ Financials Aug 19 2016
ImmuCell Corp. :ICCC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 Aug 15 2016
08-11-2016 ImmuCell Announces Second Quarter 2016 Financial Results Aug 11 2016
IMMUCELL CORP /DE/ Files SEC form 10-Q, Quarterly Report Aug 11 2016
ImmuCell Announces Second Quarter 2016 Financial Results Aug 11 2016
Q2 2016 ImmuCell Corp Earnings Release - After Market Close Aug 11 2016
08-03-2016 “ImmuCell to Announce Second Quarter 2016 Financial Results Aug 04 2016
ImmuCell to Announce Second Quarter 2016 Financial Results Aug 03 2016
IMMUCELL CORP /DE/ Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders,... Jun 16 2016
IMMUCELL CORP /DE/ Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 15 2016
IMMUCELL CORP /DE/ Files SEC form 8-K, Changes in Registrant's Certifying Accountant May 23 2016
ImmuCell Corp. :ICCC-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
5-11-2016 “ImmuCell to Announce First Quarter 2016 Financial Results: May 11 2016
IMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2016
ImmuCell Announces First Quarter 2016 Financial Results May 11 2016
IMMUCELL CORP /DE/ Files SEC form 10-Q, Quarterly Report May 11 2016
5-4-2016 “ImmuCell to Announce First Quarter 2016 Financial Results” May 04 2016
ImmuCell to Announce First Quarter 2016 Financial Results May 04 2016
4-4-2016 “Immucell Appoints Elizabeth Williams Vice President of Manufacturing Operations Apr 05 2016
ImmuCell Appoints Elizabeth Williams Vice President of Manufacturing Operations Apr 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)